RU2766345C2 - Конъюгаты бацитрацин-альгинатный олигомер - Google Patents

Конъюгаты бацитрацин-альгинатный олигомер Download PDF

Info

Publication number
RU2766345C2
RU2766345C2 RU2019109728A RU2019109728A RU2766345C2 RU 2766345 C2 RU2766345 C2 RU 2766345C2 RU 2019109728 A RU2019109728 A RU 2019109728A RU 2019109728 A RU2019109728 A RU 2019109728A RU 2766345 C2 RU2766345 C2 RU 2766345C2
Authority
RU
Russia
Prior art keywords
bacitracin
alginate oligomer
alginate
infection
residues
Prior art date
Application number
RU2019109728A
Other languages
English (en)
Russian (ru)
Other versions
RU2019109728A (ru
RU2019109728A3 (enExample
Inventor
Элейн ФЕРГЮСОН
Дэвид Уильям ТОМАС
Арне ДЕССЕН
Филип РИЕ
Original Assignee
АльгиФарма АС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АльгиФарма АС filed Critical АльгиФарма АС
Publication of RU2019109728A publication Critical patent/RU2019109728A/ru
Publication of RU2019109728A3 publication Critical patent/RU2019109728A3/ru
Application granted granted Critical
Publication of RU2766345C2 publication Critical patent/RU2766345C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C07K7/58—Bacitracins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
RU2019109728A 2016-10-21 2017-10-20 Конъюгаты бацитрацин-альгинатный олигомер RU2766345C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1617862.6 2016-10-21
GB1617862.6A GB2555391B (en) 2016-10-21 2016-10-21 Bacitracin-alginate oligomer conjugates
PCT/EP2017/076926 WO2018073448A1 (en) 2016-10-21 2017-10-20 Bacitracin-alginate oligomer conjugates

Publications (3)

Publication Number Publication Date
RU2019109728A RU2019109728A (ru) 2020-11-23
RU2019109728A3 RU2019109728A3 (enExample) 2021-02-16
RU2766345C2 true RU2766345C2 (ru) 2022-03-15

Family

ID=57738026

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019109728A RU2766345C2 (ru) 2016-10-21 2017-10-20 Конъюгаты бацитрацин-альгинатный олигомер

Country Status (16)

Country Link
US (1) US20230139922A1 (enExample)
EP (1) EP3528829B1 (enExample)
JP (1) JP7191014B2 (enExample)
KR (1) KR20190070946A (enExample)
CN (1) CN109862904A (enExample)
AU (1) AU2017345294A1 (enExample)
BR (1) BR112019007928A2 (enExample)
CA (1) CA3040796A1 (enExample)
DK (1) DK3528829T3 (enExample)
ES (1) ES2914784T3 (enExample)
GB (1) GB2555391B (enExample)
PL (1) PL3528829T3 (enExample)
PT (1) PT3528829T (enExample)
RU (1) RU2766345C2 (enExample)
SI (1) SI3528829T1 (enExample)
WO (1) WO2018073448A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12649000B2 (en) 2018-03-19 2026-06-09 Algipharma As Use of alginate oligomers to enhance the translocation of micro/nanoparticles across mucus layers
CN110484473B (zh) * 2019-08-31 2022-08-19 暨南大学 一种促进鹤羽田戴尔福特菌在植物根际定殖的方法
CN111057131A (zh) * 2019-12-13 2020-04-24 上海市食品药品检验所 一种杆菌肽及其组分的分析方法
CN111420024B (zh) * 2020-04-07 2023-10-03 中国科学院深圳先进技术研究院 杆菌酞a在制备预防和治疗冠状病毒的药物中的应用
CN112812150A (zh) * 2021-01-29 2021-05-18 深圳海创生物科技有限公司 一种活性环肽、活性环肽组合物及其在制备具有抗氧化或抗炎作用的产品中的应用
CN113413490B (zh) * 2021-05-14 2022-05-27 哈尔滨医科大学 一种超声响应性复合水凝胶及其制备方法和应用
CN117679350B (zh) * 2023-12-13 2024-06-07 诺德溯源(广州)生物科技有限公司 一种淡化痘印和抚平痘坑的愈创木组合物及其应用
WO2026008878A1 (en) * 2024-07-04 2026-01-08 Algipharma As Antimycotic polyene-alginate oligomer conjugates

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952092A (en) * 1972-06-09 1976-04-20 William Henry Bowen Oral preparations
WO2010139956A1 (en) * 2009-06-03 2010-12-09 Algipharma Ipr As Treatment of acinetobacter with alginate oligomers and antibiotics
RU2519713C2 (ru) * 2008-09-09 2014-06-20 Конинклейке Филипс Электроникс Н.В. Хелатные амфифильные полимеры
US20140364595A1 (en) * 2011-06-22 2014-12-11 Vyome Biosciences Conjugate-based antifungal and antibacterial prodrugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
US6248360B1 (en) * 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
RU2527894C2 (ru) * 2007-11-27 2014-09-10 Альгифарма ИПР АС Использование альгинатных олигомеров в борьбе с биопленками
EP3220965A1 (en) * 2014-11-20 2017-09-27 University of Southern California Use of alginate formulation for intraincisional drug delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952092A (en) * 1972-06-09 1976-04-20 William Henry Bowen Oral preparations
RU2519713C2 (ru) * 2008-09-09 2014-06-20 Конинклейке Филипс Электроникс Н.В. Хелатные амфифильные полимеры
WO2010139956A1 (en) * 2009-06-03 2010-12-09 Algipharma Ipr As Treatment of acinetobacter with alginate oligomers and antibiotics
US20140364595A1 (en) * 2011-06-22 2014-12-11 Vyome Biosciences Conjugate-based antifungal and antibacterial prodrugs

Also Published As

Publication number Publication date
SI3528829T1 (sl) 2022-07-29
CA3040796A1 (en) 2018-04-26
ES2914784T3 (es) 2022-06-16
RU2019109728A (ru) 2020-11-23
EP3528829A1 (en) 2019-08-28
JP7191014B2 (ja) 2022-12-16
DK3528829T3 (da) 2022-05-30
RU2019109728A3 (enExample) 2021-02-16
CN109862904A (zh) 2019-06-07
US20230139922A1 (en) 2023-05-04
PL3528829T3 (pl) 2022-09-19
GB2555391B (en) 2019-06-26
GB2555391A (en) 2018-05-02
BR112019007928A2 (pt) 2019-07-02
KR20190070946A (ko) 2019-06-21
PT3528829T (pt) 2022-06-02
GB201617862D0 (en) 2016-12-07
AU2017345294A1 (en) 2019-05-02
JP2019535669A (ja) 2019-12-12
WO2018073448A1 (en) 2018-04-26
EP3528829B1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
EP3528830B1 (en) Polymyxin-alginate oligomer conjugates
EP3528829B1 (en) Bacitracin-alginate oligomer conjugates
CN102497883B (zh) 用于克服细菌多重抗药性的藻酸盐低聚物
AU2008328567B2 (en) Use of alginate oligomers in combating biofilms
HK40004581A (zh) 杆菌肽-藻酸盐低聚物缀合物
HK40004580A (zh) 多粘菌素-藻酸盐低聚物缀合物